{"id":9182,"date":"2017-04-10T14:00:00","date_gmt":"2017-04-10T12:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/"},"modified":"2017-04-10T14:00:00","modified_gmt":"2017-04-10T12:00:00","slug":"irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/","title":{"rendered":"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning f\u00f6r 2016"},"content":{"rendered":"

[mfn_before_post]<\/p>\n

G\u00f6teborg den 10 april 2017<\/strong><\/div>\n

IRLAB Therapeutics AB (publ) (ticker: IRLAB A) har idag publicerat \u00c5rsredovisning f\u00f6r 2016. \u00c5rsredovisningen finns tillg\u00e4nglig p\u00e5 IRLAB:s hemsida, www.irlab.se under "Investor Relations\/Financial reports<\/a>".<\/p>\n

\n

F\u00f6r vidare information<\/strong><\/p>\n

Nicholas Waters, VD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Tel: +46 730 75 77 01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0\u00a0
E-post: nicholas.waters@irlab.se<\/a><\/p>\n

Viktor Siewertz, COO\u00a0
Tel: +46 727 10 70 70\u00a0
E-post: viktor.siewertz@irlab.se<\/a><\/p>\n

Denna information \u00e4r s\u00e5dan information som IRLAB Therapeutics AB (publ) \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 10 april 2017 kl. 14:00 CET.<\/p>\n

FNCA Sweden AB \u00e4r Bolagets Certified Adviser p\u00e5 Nasdaq First North Premier.<\/p>\n<\/div>\n

\n

Kort om IRLAB<\/strong><\/p>\n

IRLAB \u00e4r ett forsknings- och utvecklingsbolag som fokuserar p\u00e5 utveckling av nya l\u00e4kemedel f\u00f6r behandling av neurodegenerativa sjukdomar, i synnerhet Parkinsons sjukdom och demens.<\/p>\n

IRLAB har tv\u00e5 prim\u00e4ra l\u00e4kemedelskandidater, IRL752 och IRL790, med genomf\u00f6rda kliniska Fas I-studier, samt ytterligare tre projekt i preklinisk fas. IRLAB:s forskning syftar till att regelbundet ta fram nya l\u00e4kemedelskandidater med hj\u00e4lp av den unika och egenutvecklade forskningsplattformen, ISP.<\/p>\n

IRLAB \u00e4r baserat i G\u00f6teborg. IRLAB:s verksamhet bedrivs huvudsakligen genom dotterbolaget Integrative Research Laboratories Sweden AB.<\/p>\n

F\u00f6r mer information, v\u00e4nligen bes\u00f6k www.irlab.se<\/a><\/p>\n<\/div>\n

[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"

G\u00f6teborg den 10 april 2017<\/p>\n","protected":false},"template":"","class_list":["post-9182","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv","mfn-news-tag-mfn-regulatory-vpml_sv"],"acf":[],"yoast_head":"\nIRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning f\u00f6r 2016 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning f\u00f6r 2016 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg den 10 april 2017\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/\",\"name\":\"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning f\u00f6r 2016 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2017-04-10T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning f\u00f6r 2016\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning f\u00f6r 2016 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning f\u00f6r 2016 - IRLAB","og_description":"G\u00f6teborg den 10 april 2017","og_url":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/","url":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/","name":"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning f\u00f6r 2016 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2017-04-10T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/irlab-therapeutics-ab-publ-publicerar-arsredovisning-for-2016\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB Therapeutics AB (publ) publicerar \u00e5rsredovisning f\u00f6r 2016"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}